Shares of mid-cap oncology specialist Exelixis are worth about $39 each right now. The biotech generates steady revenue and ...

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers, today announced ...

McKesson MCK is making a strategic shift that will redefine its role in the healthcare ecosystem. Long known as one of the ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Cardiff Oncology, Inc. (NASDAQ:CRDF) stands against other hot biotech stocks under ...

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this article, we are going to take a look at where Kura Oncology, Inc.

DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ ...

Germany-based biotech firm Boehringer Ingelheim, which has its U.S. headquarters in Ridgefield, has acquired Nerio Therapeutics Inc., aCalifornia-based oncology biotech, for $1.3 billion, the company ...

Issued on behalf of Oncolytics Biotech Inc. Oncolytics Biotech Inc. (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling ...